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Abstract:  
A key pathology of Alzheimer’s disease (AD) is amyloid β (Aβ) accumulation which triggers 
synaptic impairments and neuronal death. Metabolic disruption is common in AD and recent 
evidence implicates impaired leptin function in AD.  Thus the leptin system may be a novel 
therapeutic target in AD. Indeed, leptin has cognitive enhancing properties and it prevents the 
aberrant effects of Aβ on hippocampal synaptic function and neuronal viability. However as 
leptin is a large peptide, development of smaller leptin-mimetics may be the best therapeutic 
approach. Thus, we have examined the cognitive enhancing and neuroprotective properties of 
known bioactive leptin fragments. Here we show that the leptin (116-130) fragment, but not 
leptin (22-56), mirrored the ability of leptin to promote AMPA receptor trafficking to 
synapses and facilitate activity-dependent hippocampal synaptic plasticity. Administration of 
leptin (116-130) also mirrored the cognitive enhancing effects of leptin as it enhanced 
performance in episodic-like memory tests. Moreover, leptin (116-130) prevented 
hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. These 
findings establish further the importance of the leptin system as a therapeutic target in AD.  
 
Introduction. 
Alzheimer's disease (AD) is a complex, progressive brain disorder that results in profound 
cognitive deficits, particularly in memory. Accumulation of toxic amyloid plaques and 
neurofibrillary tangles comprising hyper-phosphorylated tau are key pathological features of 
AD. Proteolytic processing of APP and generation of toxic amyloid beta (Aβ) is linked to 
aberrant synaptic function and neuronal degeneration. Several studies indicate that soluble Aβ 
oligomers greatly influence activity-dependent hippocampal synaptic plasticity resulting in 
deficits in learning and memory. Indeed, Aβ inhibits the induction of hippocampal long-term 
potentiation (LTP), but facilitates long-term depression (LTD; Shankar et al, 2008; Walsh et 
al, 2002). Furthermore, Aβ significantly alters AMPA receptor trafficking to and away from 
synapses which contributes to hippocampal synaptic dysfunction (Hsieh et al, 2006; Liu et al, 
2010).  
Clinical evidence indicates that diet and lifestyle are major risk factors for developing AD 
and disruption to metabolic systems is linked to AD (Stranahan and Mattson, 2012). The 
metabolic hormone leptin regulates energy homeostasis, but also markedly influences 
hippocampal synaptic function. Indeed, leptin-insensitive rodents exhibit impaired 
hippocampal LTP and spatial memory (Li et al, 2002). Moreover, direct administration of 
leptin into the hippocampus facilitates learning (Wayner et al, 2004), whereas hippocampal 
dendritic morphology, glutamate receptor trafficking and synaptic plasticity are significantly 
altered after leptin treatment (Shanley et al, 2001; O’Malley et al, 2007; Moult et al, 2010; 
Luo et al, 2015).  Clinical studies indicate that aberrant leptin function is associated with an 
increased risk of AD, as AD patients exhibit significantly lower leptin levels than normal 
(Power et al, 2001). Individuals with lower circulating leptin also have a greater risk of 
developing AD (Lieb et al, 2009). Additionally, leptin levels are markedly reduced in rodent 
models with familial AD mutations (APPSwe; PSIM146V; Fewlass et al, 2004). In cellular 
models of AD, leptin treatment prevents the aberrant effects of Aβ, as leptin reverses the 
ability of Aβ to inhibit LTP and facilitate LTD in hippocampal slices (Doherty et al, 2013) 
and it prevents Aβ-driven internalisation of the AMPA receptor subunit, GluA1 in 
hippocampal neurons (Doherty et al, 2013). Chronic intracerebroventricular injection of 
leptin also reverses Aβ-induced impairments in LTP in vivo (Tong et al, 2015). In cell 
survival assays, leptin protects against Aβ-induced toxicity as neuronal viability is increased 
after leptin treatment. Moreover the cortical expression of two AD-linked biomarkers, 
endophilin 1 and phosphorylated tau, are enhanced in leptin-insensitive Zucker fa/fa rats 
(Doherty et al, 2013). Thus there is growing evidence that leptin-based therapies may be 
beneficial in AD.  
However, using leptin therapeutically may not be the best approach due to its widespread 
central actions. One possibility is to develop small molecules that mimic leptin action. 
Indeed, studies have found that specific fragments of the leptin peptide are bioactive and 
mirror the anti-obesity effects of leptin (Grasso et al, 1997; Roshavskaya-Arena et al, 2000). 
Indeed, application of a C-terminal fragment of leptin (amino acids 116-130) or a shorter 
fragment (116-121) to leptin-deficient ob/ob mice reduced food intake and body weight 
(Grasso et al, 1997; Roshavskaya-Arena et al, 2000; Grasso et al, 2001). However, another 
leptin fragment (22-56) is also bioactive as significant reductions in food intake have been 
observed after leptin (22-56) administration (Samson et al, 1996). Thus, it is feasible that 
different parts of the leptin molecule are active in the CNS. However, the cognitive 
enhancing and neuroprotective properties of the bioactive leptin fragments are unknown. 
Here we show that leptin (116-130), but not leptin (22-56), mirrored the effects of leptin on 
hippocampal synaptic plasticity and also prevented hippocampal synaptic disruption and cell 
death induced by Aβ. Moreover, leptin (116-130) has similar cognitive enhancing effects to 
leptin as it enhanced episodic-like memory. These findings establish further the importance 
of the leptin system as a therapeutic target in AD.  
 
Methods. 
Primary Neuronal culture. 
Hippocampal cultures were prepared from neonatal Sprague Dawley rats as before (O’Malley 
et al, 2007). Briefly, neonatal Sprague Dawley rats (1–3 days old) were killed by cervical 
dislocation in accordance with Schedule 1 of the United Kingdom Government Animals 
(Scientific Procedures) Act, 1986 and the hippocampi removed. After washing in HEPES 
buffered saline (HBS) comprising (mM): NaCl 135; KCl 5; CaCl2 1; MgCl2 1; HEPES 10; D-
glucose 25 at pH 7.4; cells were treated with protease Type X and Type XIV (0.5 mg/ml; 
Sigma) for 25 min at room temperature. Dissociated cells were plated onto sterile dishes 
(Falcon 3001) treated with poly-l-lysine (20 μg/ml; 1-2 h) and maintained in MEM with 
serum replacement-2 (Sigma) in a humidified atmosphere of 5% CO2 and 95% O2 at 37 °C 
for up to 3 weeks. 
 
Human Neural Cell Line SH-SY5Y 
The human neuroblastoma cell line, SH-SY5Y (ECACC, UK) was maintained in Dulbecco’s 
Modified Eagle Medium supplemented with glucose (4500µg/l) and 10% (v/v) cosmic calf 
serum (Fisher Scientific, UK) at 37°C in a humidified atmosphere of 5% CO2, 95% air and 
allowed to reach 70-80% confluence before seeding. Cells (passage 10-18) were plated at 
10,000 cells per well in 96 well tissue culture plates (Nunc, VWR, UK) and at a density of 
2X105 cells in 35mm dishes for protein extraction. To induce differentiation, cells were 
cultured in DMEM supplemented with glucose (4500µg/l), 1% (v/v) cosmic calf serum and 
10M retinoic acid for 5 days. Thereafter they were incubated in DMEM supplemented with 
glucose (4500µg/l), serum replacement 2 (2%; Sigma, UK) and 18M 5-fluorodeoxyuridine 
to inhibit proliferation of undifferentiated cells. 50% of the medium was changed every 2-3 
days and pharmacological treatment was carried out 7 days after switching to this medium. 
Reagents used were (from Sigma UK unless stated) 0.1-10nM human leptin and leptin (116-
130); 0.1-10nM leptin (22-56; Bachem; Switzerland); 5 copper chloride; 10mM A1-42; 
5M WP1066 or 50nM wortmannin. All treatments were added to the culture at the same 
time and survival assays were carried out after 96 hours treatment. Protein samples for 
ELISA were extracted 3 hours after exposure to the relevant reagents 
 Cell Survival Assays 
The concentration of lactate dehydrogenase in the culture medium (LDH) was used to 
monitor the level of cell death, as previously (Oldrieve and Doherty, 2010). A Crystal violet 
assay was used to assess total cell number. Cells were fixed in neutral buffered formalin and 
washed 3 times in PBS prior to staining with 0.01% crystal violet acetate for 5 min. Plates 
were washed 5-10 times in dH20 and cells solubilised in 100l DMSO before reading the 
absorbance on a Biohit BP100 plate reader. For both assays, data is expressed as percentage 
relative to control, untreated wells to normalise for differences in plating density between 
individual experiments. 
 
ELISA for cell signalling pathways 
Protein from cultures was extracted into 500µl Tris-buffered saline containing protease 
inhibitor cocktail, and a Bradford assay used to determine protein concentration. Samples 
were diluted to give equal loading onto ELISA plates. Commercially available ELISA kits 
were used in accordance with the manufacturer’s instructions to determine the ratio of pan-
STAT3 to phospho-STAT3 (Sigma, UK) and pan-Akt to phospho-Akt (Sigma, UK). Each 
protein sample was run in duplicate.  
 
Surface labelling of AMPA receptors. 
To monitor GluA1 surface expression, immunocytochemistry was performed on hippocampal 
cultures (7-14 DIV) as before (Moult et al, 2010). Neurons were treated with agents for 20 
min at room temperature (20-22 oC) before incubation with an antibody against an N-terminal 
region of GluA1 (sheep anti-GluR1; in house antibody against synthetic peptide 
(RTSDSRDHTRVDWKR) corresponding to 253–267 residues of GluR1; 1:100; Moult et al, 
2010) at 4oC. Neurons were then fixed with 4% paraformaldehyde (5 min) before adding an 
appropriate fluorescently-labelled secondary antibody (1:250; 30 min) to enable visualisation 
of GluA1 surface staining. No labeling was observed after incubation with secondary 
antibody alone. For synaptic co-localization studies, surface GluA1 staining was compared 
with synaptophysin (anti-synaptophysin antibody) immunolabelling and percentage of 
surface GluA1 at synapses was assessed as the number of GluA1-positive sites that colocalize 
with synaptophysin-positive sites. 
An Axiovert 200M laser scanning confocal microscope was used for image acquisition and 
analysis. Dual labeling images were obtained in multi-tracking mode using a 15 s scan speed. 
Intensity of staining was determined off-line using Lasersharp software (Carl Zeiss). Analysis 
lines (50 μm) were drawn along randomly selected dendritic regions (50 nm), and mean 
fluorescence intensity was calculated. Data were obtained from at least four randomly 
selected cells for each condition, and all data were obtained from at least three different 
cultures from different animals. Within a given experiment, all conditions, including 
illumination intensity and photomultiplier gains, were kept constant. To quantify 
experimental data obtained from separate days, data were normalized relative to mean 
fluorescence intensity in control neurons. 
 
Hippocampal slice preparation and electrophysiology. 
Parasagittal hippocampal slices (300 µm) were prepared from either P13-21 or 12-24 week 
old male Sprague Dawley rats as previously (Moult et al, 2010). Brains were rapidly removed 
and placed in ice-cold artificial CSF (aCSF; bubbled with 95% O2 and 5% CO2) containing 
the following (in mm): 124 NaCl, 3 KCl, 26 NaHCO3, 1.25 NaH2PO4, 2 CaCl2, 1 MgSO4, 
and 10 d-glucose. Once prepared, parasagittal slices were allowed to recover at room 
temperature in oxygenated aCSF for 1 h before use. Slices were transferred to a submerged 
chamber maintained at room temperature and perfused with artificial cerebrospinal fluid at 
2mlmin-1. Standard extracellular recordings were used to monitor evoked field excitatory 
postsynaptic potentials (fEPSP) from stratum radiatum. The Schaffer collateral-commissural 
pathway was stimulated (constant voltage; 0.1ms) at 0.033 Hz, using a stimulus intensity that 
evoked a peak amplitude ∼50% of the maximum. Synaptic potentials were low pass filtered 
at 2 kHz and digitally sampled at 10 kHz. The fEPSP slope was measured and expressed 
relative to baseline. Synaptic records are the average of four consecutive responses and 
stimulus artefacts are blanked for clarity. 
LTP was induced using a high frequency stimulation paradigm (10 trains; 8 stimuli; 100Hz), 
whereas the sub-threshold LTD paradigm used was low frequency stimulation (LFS; 1 Hz) 
for 5 min (300 shocks; 15). A primed burst stimulation paradigm (5 trains of 8 stimuli at 
100Hz; Rose and Dunwiddie, 1986) was used to induce STP.  Recordings were made using 
an Axopatch 200B amplifier and analysed using LTP v2.4 software (Anderson and 
Collingridge, 2007). In all experiments, the slope of fEPSPs was monitored continuously. For 
studies comparing the actions of leptin and the fragments on synaptic transmission, the mean 
slope (average of 5 min recording) of fEPSPs obtained during the 5 min period immediately 
prior to leptin and/or agent addition was compared to that after 25-30 min exposure to the 
agent. In synaptic plasticity studies, the degree of potentiation or depression was calculated 
30-35 min after LFS or HFS and expressed as a percentage of baseline ± SEM. 
 
Episodic-like memory testing 
Mice were tested using the same protocol used to test object-place-context (OPC) recognition 
in rats (Wilson et al, 2013). The size of the testing box was reduced to 30cm x 20cm x 20cm 
and the household objects used in the task were approximately the size of the mice in at least 
one dimension. The box could be configured with two sets of contextual features (white vs. 
stripes) by using different wall and floor inserts. These created one environment that was 
plain white and one that had stipes and a mesh floor. Mice were handled extensively prior to 
training and then habituated to the box for 4 days before undergoing object recognition, 
object-place and object-context training. These data are not presented and served only to 
familiarise the mice to the testing procedures and the factors that are manipulated during the 
OPC task. On the OPC testing days, mice were given IP injections of either saline, leptin or 
leptin (116-130, both at 7.8nM/ml) 30 minutes prior to testing. Testing consisted of three 
stages; 2 sample phases and a test phase (illustrated in Fig 7A). Each phase was three min 
duration and exploration behaviour was scored using custom written software (Observe, 
University of St Andrews). Between all phases the box was cleaned and dried using F10 
solution. All testing was recorded on a webcam connected to a laptop to allow offline scoring 
of behaviour. Twenty percent of trials were rescored by a researcher who was blind to the 
group identity of the mice and these scores were found to be within 10% of the original 
scoring. The dependent variable measured was a discrimination index which is calculated by 
subtracting the amount of time exploring the familiar object from the amount of time 
exploring the novel object and dividing by the total amount of exploration. This measure was 
taken from the first minute of the test trial as novelty discrimination has been shown to 
rapidly diminish after the first minute (Clarke et al., 2000). 
 
Statistical Analyses. 
In immunocytochemical studies, data are expressed as mean ± SEM and statistical analyses 
performed using one-way ANOVA with Tukey’s post hoc test for comparisons between 
multiple groups. In electrophysiological studies, analyses were performed using repeated 
measures ANOVA for comparison between multiple groups. A one-way ANOVA with 
Tukey’s post hoc test was used for comparison between multiple groups in cell viability 
assays. In ELISA assays, a t-test was used to determine differences between groups. P<0.05 
was considered significant. In behavioural studies a one-way ANOVA with Tukey’s post hoc 
tests was used for comparison between the groups. 
Materials. 
Recombinant human leptin (R&D Systems, Europe) was used in all experiments. Leptin was 
prepared as a 50 µM stock solution in normal aCSF and was diluted to the required 
concentration in aCSF or HBS. Aβ1–42 peptide was synthesized and purified by Dr. Elliott at 
Yale University (New Haven, CT, USA) based on the human Aβ sequence. The lyophilized 
powder was solubilized in dimethyl sulfoxide (DMSO) and diluted to a working 
concentration. For cell viability and biochemical assays Aβ was prepared as described 
previously as Aβ has shown to elicit toxicity when in a β sheet conformation (Simmons et al., 
1994). Briefly, lypholized powder was solubilized in dH2O to a concentration of 1 mM in 
phosphate-buffered saline and incubated for 24 hours at 37 °C prior to further dilution to 
working concentration in culture medium. Wortmannin, bisperoxovanadium (Calbiochem), 
WP1066 (Cayman Chemicals) and D-AP5 (Tocris Cookson) were all obtained commercially. 
 
Results  
Leptin (116-130) facilitates NMDA receptor-dependent hippocampal synaptic plasticity. 
It is known that NMDA receptors contribute little to basal excitatory synaptic transmission 
but synaptic activation of NMDA receptors is crucial for LTP induction at hippocampal 
synapses (Bliss and Collingridge, 1993). Previous studies indicate that leptin enhances the 
magnitude of activity-dependent LTP in acute hippocampal slices (Oomura et al, 2006) and 
following direct administration into the hippocampus in vivo (Wayner et al, 2004). We have 
also shown that leptin facilitates NMDA receptor-dependent synaptic plasticity as leptin 
promotes conversion of short term potentiation (STP) to hippocampal LTP (Shanley et al, 
2001). In order to compare the effects of leptin and the leptin fragments on synaptic plasticity 
in juvenile hippocampal slices (P13-21), a primed burst stimulation paradigm (5 trains of 8 
stimuli at 100Hz; Rose and Dunwiddie, 1986) was used to induce STP, which returned to 
baseline levels within 30-35 min (n=4; Fig 1A). In accordance with previous studies (Shanley 
et al, 2001), application of leptin (50nM) prior to the stimulation paradigm converted STP 
into a persistent increase in synaptic transmission (155 ± 6.1% of baseline at 40 min; n=4; 
p<0.05; Fig 1A). Similarly, treatment with 50nM leptin (116-130) facilitated synaptic 
plasticity as synaptic transmission was enhanced to 143 ± 6.4% of baseline in leptin (116-
130)-treated slices (n=4; p<0.05; Fig 1B). In contrast, in slices exposed to 50nM leptin (22-
56), only STP was observed as synaptic transmission returned to baseline levels within 40 
min (n=6; Fig 1C). 
 
Leptin (116-130) induces synaptic plasticity at adult hippocampal CA1 synapses. 
We have shown that leptin regulation of excitatory synaptic transmission is age-dependent. Thus in 
contrast to its effects in juvenile tissue, leptin (25nM) induces a novel form of LTP in adult 
hippocampus (Moult and Harvey, 2011). In order to verify if the leptin fragments mirror leptin 
action in adult tissue, the effects of the leptin fragments were examined in hippocampal slices from 
adult (12-24 week) rats. In accordance with previous studies (Moult et al, 2010; Moult and Harvey, 
2011), application of leptin (25nM; 20 min) to adult slices rapidly enhanced synaptic transmission 
(to 188 ± 13% of baseline; n=4; p<0.01; data not shown) which was sustained for the duration of 
recordings. Synaptic transmission was also markedly increased (to 140 ± 13% of baseline; n=5; 
p<0.05; Fig 2A) after treatment with 25nM leptin (116-130), whereas application of 25nM leptin 
(22-56) had no significant effect on synaptic efficacy (99 ± 2% of baseline; n=4; p>0.05; Fig 2B). 
These data indicate that leptin (116-130) mirrors the ability to leptin to enhance synaptic efficacy in 
adult hippocampus.  
 
Leptin (116-130), but not leptin (22-56) enhances the surface expression of GluA1. 
Trafficking of AMPA receptors to and away from synapses is crucial for various forms of activity-
dependent synaptic plasticity (Collingridge et al, 2004). Our studies indicate that leptin regulates 
AMPA receptor trafficking as leptin promotes trafficking of GluA1 to hippocampal synapses 
(Moult et al, 2010). Moreover the ability of leptin to induce LTP in adult hippocampus requires the 
delivery of GluA1 to synapses by leptin (Moult et al, 2010). Thus, to assess if the leptin fragments 
also influence AMPA receptor trafficking processes, the surface expression of GluA1 was assayed 
in cultured hippocampal neurons (Moult et al, 2010). In agreement with previous studies, 
application of leptin (50nM; 15min) increased surface GluA1 expression to 184 ± 7%; (n=36; 
p<0.001; Fig 2C&D) compared to control hippocampal neurons. Similarly GluA1 surface 
expression was elevated (to 160 ± 6 % of control; n=36; p<0.001) after exposure to 50nM leptin 
(116-130; Fig 2C&D), whereas GluA1 surface expression (98 ± 4% of control; n=36; p> 0.05) was 
not altered after treatment with 50nM leptin (22-56). These data indicate that leptin (116-130), but 
not leptin (22-56) mirrors the plasticity enhancing effects of leptin by increasing GluA1 surface 
expression in hippocampal neurons.   
 
As excitatory synaptic strength is governed by the density of AMPA receptors expressed at 
synapses, the effects on synaptic AMPA receptors was examined by comparing the co-localisation 
between surface GluA1 and synaptophysin immunolabelling in hippocampal cultures (Moult et al, 
2010). In agreement with previous studies (O’Malley et al, 2007; Moult et al, 2010), leptin (50nM; 
30 min) increased synaptophysin staining to 144 ± 9% of control (n=48; p<0.001) and it also 
enhanced the degree of co-localisation between surface GluA1 and synaptophysin immunostaining 
from 43 ± 5.4% to 62 ± 4.4% (n=36; p<0.05; Fig 2E). Similarly, in hippocampal neurons treated 
with leptin (116-130), synaptophysin staining was increased to 122 ± 9% (n=36; p<0.05) and a 
significant increase (to 64 ± 4.9%; n=36; p<0.01) in GluA1-synaptophysin co-localisation was 
observed (Fig 2E). Conversely, exposure to leptin (22-56) had no significant effect on either 
synaptophysin staining (105 ± 9%; n=36; p>0.05) or the degree of co-localisation (49 ± 5.4%; 
n=36; p>0.05; Fig 2E).  These data indicate that leptin (116-130), but not leptin (22-56) promotes 
the trafficking of GluA1 to synapses in hippocampal neurons. 
 
Inhibition of the phosphatase, PTEN underlies leptin-driven trafficking of GluA1 to synapses 
(Moult et al, 2010). In order to determine if similar leptin dependent signalling cascades mediate 
the actions of leptin (116-130), the effects of pharmacological inhibition of PTEN with 
bisperoxovanadium (bpV; Schmid et al, 2004) were assessed in hippocampal cultures. Application 
of bpV (50nM; 30 min) increased GluA1 surface expression to 148 ± 8% of control (n=36; 
p<0.001; Fig 2F). In accordance with previous studies (Moult et al, 2010), leptin resulted in a 
significant increase in surface GluA1 labelling (140 ± 7.2%; n=36; p<0.001; Fig 2F). Similarly, 
GluA1 surface expression was enhanced (to 167 ± 10% of control; n=36; p<0.001) after exposure 
to leptin (116-130). Moreover, treatment with bpV occluded the effects of either leptin or leptin 
(116-130) such that GluA1 staining was 131 ± 6.6% and 148 ± 8.1% of control (n=36; p<0.001; for 
both; Fig 2F) in the presence of bpV and either leptin or leptin (116-130), respectively. These data 
indicate that the ability of leptin (116-130) to regulate GluA1 trafficking involves inhibition of 
PTEN. 
 
Leptin (116-130), but not leptin (22-56) reverses Aβ1-42 inhibition of hippocampal 
synaptic plasticity 
Several studies indicate that soluble Aβ oligomers impair activity-dependent synaptic 
plasticity, as exposure to Aβ inhibits hippocampal LTP (Shankar et al, 2008; Li et al, 2009) 
and enhances LTD (Shankar et al, 2008). Moreover, our recent studies indicate that leptin 
reverses the detrimental effects of Aβ1-42 on both LTP and LTD (Doherty et al, 2013). Thus 
we assessed if either of the fragments mirrored the protective actions of leptin on 
hippocampal synaptic plasticity. Initially we determined that application of leptin prevented 
the acute effects of Aβ1-42 on LTP. In control slices, synaptic plasticity was induced using 
high frequency stimulation (HFS; 100 Hz 10 trains of 8 stimuli) which increased synaptic 
transmission to 127 ± 3.4% of baseline (n =8; p<0.01). Similarly in slices treated with the 
inactive peptide Aβ42–1 (1 μM; 40 min), an enhancement of synaptic transmission (132 ± 
8.8% of baseline) was induced (n=5; p<0.05; Figure 3A). However in accordance with 
previous studies (Doherty et al, 2013), exposure to Aβ1-42 not only blocked hippocampal 
synaptic plasticity (96 ± 7.5% of baseline; n=5; p>0.05; Fig 3A) but this effect was reversed 
by leptin (25nM; 135 ± 6.3% of baseline; n=4; p<0.05; Fig 3B). Similarly, treatment with 25 
nM leptin (116-130) before Aβ1–42 resulted in a robust increase in synaptic transmission (to 
136 ± 5.5% of baseline; n=6; p<0.05; Fig 3C). In contrast, HFS failed to increase synaptic 
efficacy (107 ± 3.3% of baseline; n=5; p>0.05) in slices exposed to Aβ1–42 and leptin (22-56; 
Fig 4D), although some STP was observed.  Thus these data indicate that like leptin, leptin 
(116-130) prevents the detrimental effects of Aβ1–42 on hippocampal synaptic plasticity. 
 
Leptin (116-130) reverses Aβ1-42-induced LTD. 
It is known that oligomeric Aβ promotes the induction of LTD (Shankar et al, 2008) and that 
exposure to a low concentration of leptin (10 nM) prevents facilitation of hippocampal LTD 
by Aβ1-42 (Doherty et al, 2013). Thus we assessed if either of the leptin fragments mirror 
leptin action. Initially we verified that leptin prevented Aβ1-42-induced LTD. In agreement 
with previous studies (Doherty et al, 2013), application of the sub-threshold LFS paradigm 
failed to induce LTD in vehicle-treated slices (94 ± 5.6% of baseline; n=5; p>0.05), whereas 
robust LTD (73 ± 3.8% of baseline; n=5; p<0.001) was induced in Aβ1-42 –treated slices (Fig 
4A). Furthermore, leptin (10nM) reduced the magnitude of Aβ1-42-induced LTD such that 
LFS depressed synaptic transmission to 101 ± 5.3% of baseline in leptin-treated slices (n=4; 
p>0.05; Fig 4B).  To establish if the leptin fragments mirrored leptin action the effects of 
leptin (116-130) or leptin (22-56) were also examined. Application of 10nM leptin (116-130) 
or leptin (22-56) had no significant effect on basal synaptic transmission (n=6 for leptin (116-
130) and n=5 for leptin (22-56)). Application of 10nM leptin (22-56) failed to alter the 
magnitude of Aβ1-42-induced LTD such that synaptic transmission was depressed to 73 ± 
4.0% of baseline (n=5; p<0.001; Fig 4D). In contrast, a significant reduction in the magnitude 
of Aβ1–42-induced LTD (94 ± 5.2% of baseline; n=5; p>0.05; Fig 4C) was observed in 
hippocampal slices treated with leptin (116-130; 10nM; 45 min) indicating that leptin (116-
130) also inhibits facilitation of LTD by Aβ1–42. Thus these data indicate that leptin (116-
130), but not leptin (22-56) reverses Aβ1–42-induced facilitation of LTD.  
Leptin (116-130) prevents Aβ-induced internalization of GluA1 
Previous studies indicate that Aβ promotes internalisation of the AMPA receptor subunit, 
GluA1 (Hsieh et al, 2006; Liu et al, 2010); an effect that is prevented by leptin (Doherty et al, 
2013). To determine if the leptin fragments mirror this effect, the cell surface density of 
GluA1 was probed in cultured hippocampal neurons (Moult et al, 2010). In accordance with 
previous studies (Doherty et al, 2013), treatment with Aβ1–42 (500 nM; 20 min) significantly 
attenuated (to 70 ± 2% of control) GluA1 surface expression compared with control (Aβ42–1-
treated) hippocampal neurons (n=48; p<0.001; Fig. 4E). Application of a low concentration 
of leptin (10nM) induced a small increase in GluA1 surface expression (113 ± 7% of control; 
n=36; p<0.01). However, in leptin-treated neurons, Aβ1–42 failed to significantly alter GluA1 
surface expression (101 ± 4% of control; n=36; P>0.05). In contrast, treatment with a low 
concentration (10nM) of leptin (22-56) had no significant effect on GluA1 trafficking per se 
(n=36; p>0.05). Moreover, leptin (22-56) failed to prevent the effects of Aβ on GluA1 
trafficking as surface GluA1 was reduced to 51 ± 2% of control (n=36; p<0.001) in the 
presence of Aβ and leptin (22-56; Fig 4E). Conversely, after exposure to leptin (116-130), 
Aβ1–42 failed to significantly reduce GluA1 surface expression (97 ± 4% of control; n=36; 
p>0.05). These data indicate that leptin (116-130) mirrors leptin action by preventing Aβ1-42-
induced internalisation of GluA1 in cultured hippocampal neurons.  
 
Leptin (116-130) prevents copper and Aβ-induced cell death 
We have demonstrated previously that leptin attenuates cortical neuronal death triggered by 
A1-42 or divalent copper ions (Doherty et al, 2013). To determine whether leptin (116-130) 
has neuro-protective actions, the effects of leptin (116-130) on the viability of differentiated 
human neural cells (SH-SY5Y) was examined after exposure to either 5 CuCl2 or 10M 
A1-42. Cells were treated with the toxin alone or with a range of concentrations (10 - 0.1nM) 
of leptin or leptin (116-130). Determination of membrane leakage by lactate dehydrogenase 
(LDH) assay revealed a significant reduction in LDH release after treatment with either leptin 
or leptin (116-130; both 0.1-10nM).  Thus for CuCl2-treated cells, 10nM leptin reduced LDH 
release by 39.5 ± 2.73% compared to CuCl2 alone (n=5; p<0.001; Fig 5A); an effect that was 
mirrored by 10nM leptin (116-130; 45.6 ± 2.92% (n=5; p<0.001; Fig 5A). In A1-42 treated 
cells, leptin also significantly reduced LDH release by 31.8 ± 13.2% (0.1nM) and 47.9 ± 
7.45% (10nM), respectively (n=5; p<0.001; Fig 5B). Similarly, application of 0.1nM or 
10nM leptin (116-13) decreased LDH release by 26.7 ± 17.3% or 46.6 ± 9%, respectively 
(n=5; p<0.05; Fig 5B). Thus like leptin, treatment with leptin (116-130) reduces neuronal 
death in response to AD-linked toxins in vitro. 
In parallel studies a crystal violet assay was used to verify these findings by assessing cell 
number. In CuCl2-treated cells, there was a concentration-dependent increase in the survival 
of cells treated with either leptin or leptin (116-130). Thus, treatment with leptin (0.1nM) 
resulted in a 16.7 ±3.4% increase in cell number and this increased to 43.4 ±9.2% in the 
presence of 10nM leptin (n=5; p<0.01). Similarly, exposure to 0.1nM or 10nM leptin (116-
130) increased cell number by 27.8 ±10.6% and 39.9 ± 13.5%, respectively (n=5; Fig 5C). 
Treatment with leptin (116-130) also mirrored leptin action by increasing cell viability in 
A1-42-treated cultures as cell number increased by 19.2 ± 15% and 44.3 ± 7.5% after 
treatment with 0.1nM or 10nM leptin, respectively (n=5 for each; p<0.01). Exposure to leptin 
(116-130) also resulted in significant increases in cell number (0.1nM: 29.4 ± 9.4% increase; 
10nM: 51.8 ± 6.3% increase; n=5 for both; p<0.001; Fig 5D).  
As leptin (22-56) has biological activity in other systems, the specificity of the leptin (116-
130) fragment in promoting cell survival was examined by determining whether leptin (22-
56) inhibited neuronal death induced by Aβ1-42. In contrast to leptin (116-130), treatment with 
leptin (22-56) had no effect on the viability of cells exposed to A1-42 (41.2 ± 5.8% survival 
following A1-42 treatment and 48.6 ± 9.3% in A1-42 with 10nM leptin (22-56) treated cells; 
n=5; p>0.5; data not shown). These data reveal a potent neuroprotective effect of the leptin 
fragment (116-130) that is comparable to the survival actions of leptin. Moreover, this anti-
apoptotic response is specific to leptin (116-130) as leptin (22-56) failed to influence 
neuronal viability.  
The neuroprotective effects of leptin (116-130) involve activation of STAT3 and PI3-
kinase-dependent signalling pathways 
Our previous studies indicate a crucial role for STAT3 and PI3-kinase/Akt signalling in the 
neuroprotective actions of leptin (Doherty et al, 2013). To determine whether leptin (116-
130) acts via similar signalling cascades we examined the effects of pharmacological 
inhibitors of STAT3 (WP1066) or PI3-kinase (wortmannin). In A1-42-treated SH-SY5Y 
cells, application of either inhibitor significantly reduced the ability of leptin (116-130) to 
alleviate neuronal death. When neurons were treated with the STAT3 inhibitor, an 18.3 ± 
3.2% increase in LDH release in leptin (116-130) and A1-42-treated cultures was observed, 
which is similar to the 26.7 ± 4.4% increase observed with A1-42 alone (n=5; p>0.5; Fig 6A). 
Thus STAT3 inhibition blocks the neuroprotective actions of leptin (116-130), suggesting a 
role for STAT3 in this process. Furthermore, following inhibition of PI3-kinase with 
wortmannin an 26.9 ± 9.8% increase in LDH release was observed in leptin (116-130) and 
A1-42-treated cells which is not significantly different from cells treated with A1-42 alone 
(n=5; p>0.5; Fig 6B). Thus these data also indicate a role for PI3-kinase in mediating the 
neuroprotective actions of leptin (116-130).   
To verify that leptin (116-130) directly activates these signalling pathways, SH-SY5Y cells 
were exposed to 1nM leptin (116-130; 3 h) or left untreated prior to protein extraction for 
ELISA. The ratio of phosphorylated STAT3 to pan STAT3 increased markedly following 
leptin (116-130) administration (n=3; p<0.01; Fig 6C). Similarly an increase in the ratio of 
phosphorylated Akt to pan Akt was observed following exposure to leptin (116-130; n=3; 
p<0.01; Fig 6D). These data indicate that leptin (116-130) reduces cell death by a mechanism 
involving activation of STAT3 and PI3-kinase. Furthermore, exposure to leptin (116-130) 
resulted in a significant increase in the active components of these signalling cascades.   
Leptin (116-130) enhances episodic-like memory 
The current data demonstrate that leptin (116-130) enhances hippocampal synaptic plasticity 
mechanisms and has neuroprotective effects. To further assess its therapeutic potential we 
next asked if this fragment has similar cognitive enhancing properties to the whole leptin 
molecule. Previous studies indicate that leptin enhances hippocampal-dependent memory 
(Oomura et al, 2006; Farr et al, 2006), whereas resistance to leptin results in impaired spatial 
memory (Li et al, 2002). We used the object-place-context (OPC) recognition task which 
models human episodic memory, the first cognitive process to be compromised in the early 
stages of AD (Swainson et al, 2001). Performance on this task has been shown to be impaired 
in murine models of AD (Davis et al, 2013) and is compromised in animals with lesions of 
hippocampus (Langston and Wood, 2010) and lateral entorhinal cortex (Wilson et al, 2013). 
The task is based on the object recognition paradigm and models the integrated aspect of 
human episodic memory by exposing rodents to novel combinations of objects, the spatial 
locations in which they are experienced and the contextual features of the environment (see 
Fig 7A; Eacott and Norman, 2004). 42 C57/BL6 mice were habituated to a testing 
environment and then trained on object recognition, object-place recognition and object-
context recognition. Following training mice were tested on 4 days of the episodic-like OPC 
task. On these days mice were assigned to one of three groups (control, leptin, or fragment) 
and on each day mice were given 100 µl IP injections of saline, 7.8nM/ml leptin, or 
7.8nM/ml leptin (116-130) 30 min prior to testing. One-way ANOVA on the discrimination 
indices during the first minute of the test phase revealed a significant effect of group (Fig 7B; 
F(2,41) = 4.318, p=0.02). Posthoc comparisons (Tukey’s HSD) revealed that both the leptin and 
leptin (116-130) treated mice showed enhanced performance on the task relative the control 
group (p<0.05) and did not differ from each other. One sample t-tests confirmed that all 
groups performed significantly better than chance level performance (p<0.01). Finally 
analysis of the overall exploration time in both sample and test phases of the task revealed no 
change in total levels of exploration between groups demonstrating that neither leptin nor 
leptin (116-130) produced a non-specific change in exploration behaviour (Fig 7C; p>0.05). 
The increased discrimination index was driven by an increase in exploration of the novel 
object combined with a decrease in the exploration of the familiar object (Figure 7D). 
Together these data indicate that leptin (116-130) mirrors leptin’s action by enhancing 
performance in episodic-like memory tasks. 
 
Discussion  
It is well established that the hormone leptin circulates in the plasma and enters the brain via 
transport across the blood brain barrier. In the hypothalamus, leptin plays a major role in 
regulating food intake and body weight (Spiegelman and Flier, 2001). However, the central 
actions of the hormone leptin are not restricted to the hypothalamus and the regulation of 
energy homeostasis. Indeed, a number of extra-hypothalamic brain regions, including the 
hippocampus display high levels of leptin receptor expression (Irving and Harvey 2014). 
Leptin mRNA and protein are also highly expressed in the hippocampal formation (Morash et 
al, 1999) and emerging evidence suggests brain-specific production of leptin (Eikelis et al, 
2006). Thus it is likely that a combination of locally released leptin as well as peripherally-
derived leptin reach hippocampal synapses and can influence synaptic function. Indeed, 
numerous studies indicate that leptin has potential cognitive enhancing properties as it readily 
facilitates the cellular events underlying hippocampal learning and memory. Thus, leptin has 
rapid effects on activity-dependent synaptic plasticity, glutamate receptor trafficking and 
dendritic morphology (Irving and Harvey, 2014). In addition, several studies have identified 
neuroprotective effects of leptin as the viability of central and peripheral neurons is markedly 
influenced by this hormone (Doherty et al, 2008; Weng et al, 2007; Guo et al, 2008). Recent 
clinical evidence has established a link between circulating leptin levels and the incidence of 
AD (Power et al, 2001; Lieb et al, 2009), which has fuelled the possibility of using the leptin 
system as a novel therapeutic target in AD. Indeed, treatment of various AD models with 
leptin prevents the detrimental effects of Aβ that occur at both early and late stages of the 
disease (Fewlass et al, 2004; Doherty et al, 2013; Farr et al, 2006). However, as leptin is a 
very large peptide, developing small leptin-like molecules may be a better therapeutic 
approach. Several fragments of the leptin peptide are biologically active and mirror the anti-
obesity effects of leptin (Grasso et al, 1997; Grasso et al, 2001; Rozhavskaya-Arena et al, 
2000). However, the cognitive enhancing and neuroprotective effects of the leptin fragments 
are not known. Here we provide the first compelling evidence that leptin (116-130), but not 
leptin (22-56), has a potent effect on hippocampal synaptic function as it promotes trafficking 
of AMPA receptors to synapses and facilitates hippocampal synaptic plasticity. Moreover in 
cellular models that mimic amyloid toxicity, leptin (116-130), but not leptin (22-56) prevents 
the aberrant effects of Aβ on hippocampal synaptic function and neuronal viability. These 
findings indicate that one particular leptin fragment, namely (116-130), mirrors the beneficial 
actions of leptin in preventing the detrimental effects of Aβ at the early and late stages of AD. 
Finally we have shown that the leptin fragment that enhances hippocampal synaptic plasticity 
and has neuroprotective effects, namely leptin (116-130), is also a cognitive enhancer as it 
improves performance on tests of episodic memory. 
Here we show that, in accordance with previous studies (Wayner et al, 2004; Shanley et al, 
2001), NMDA receptor-dependent synaptic plasticity is enhanced by leptin as treatment with 
leptin promoted conversion of STP into a persistent increase in synaptic transmission in 
juvenile hippocampal slices. Similarly exposure to the leptin fragment (116-130) readily 
facilitated synaptic plasticity as an increase in synaptic strength was evident in leptin (116-
130), but not leptin (22-56)-treated slices. We have shown that the efficacy of excitatory 
synaptic transmission is also regulated by leptin in adult hippocampus (Moult et al, 2010). In 
agreement with this, application of either leptin or leptin (116-130) to adult hippocampal 
slices resulted in the induction of a persistent increase in synaptic transmission. In contrast, 
however leptin (22-56) failed to alter excitatory synaptic strength in adult hippocampus.  
AMPA receptor trafficking is pivotal for activity-dependent synaptic plasticity (Collingridge 
et al, 2004) and leptin regulates trafficking of GluA1 to synapses (Moult et al, 2010). In this 
study, treatment with either leptin or leptin (116-130) increased GluA1 surface expression in 
cultured hippocampal neurons, whereas leptin (22-56) was without effect. In co-localisation 
studies, the density of GluA1 subunits associated with synapses was increased after 
application of leptin or leptin (116-130), suggesting that leptin (116-130) parallels the actions 
of leptin by boosting the synaptic insertion of AMPA receptors. We have shown that leptin-
driven trafficking of GluA1 involves inhibition of PTEN (Moult et al, 2010). Similarly in this 
study, the ability of leptin (116-130) to influence GluA1 trafficking involves inhibition of 
PTEN, as application of the PTEN inhibitor bpV blocked the increase in GluA1 surface 
expression induced by leptin (116-130) in hippocampal neurons. These data indicate that like 
leptin, treatment with leptin (116-130) promotes GluA1 trafficking to hippocampal synapses 
via inhibition of PTEN. Thus, overall these data indicate that the leptin fragment (116-130) 
mirrors the actions of leptin as it markedly influences the cellular events underlying learning 
and memory by regulating AMPA receptor trafficking.   
 
It is known that Aβ inhibits the induction of hippocampal LTP (Shankar et al, 2008), and this 
detrimental effect of Aβ1-42 is reversed by leptin (Doherty et al, 2013). Similarly, leptin (116-
130) reversed the acute effects of Aβ1-42 in this study as synaptic plasticity was readily 
induced in hippocampal slices exposed to leptin (116-130) and Aβ1-42. Contrastingly, 
application of leptin (22-56) failed to prevent the detrimental effects of Aβ1-42 as no increase 
in synaptic strength was induced after exposure to Aβ1-42 and leptin (22-56). However, in 
slices exposed to leptin (22-56) post-tetanic potentiation (PTP) and some STP was observed 
after HFS, suggesting that this fragment may influence the transient enhancement of synaptic 
strength induced by HFS. As PTP and STP are thought to involve presynaptic expression 
mechanisms (Zucker and Regehr, 2002; Lauri et al, 2007), it is feasible that leptin (22-56) 
can act pre-synaptically to influence glutamate release mechanisms.  
Several studies indicate that Aβ1-42 also facilitates the induction of hippocampal LTD 
(Shankar et al, 2008; Li et al, 2009), and this effect is also reversed by leptin (Doherty et al, 
2013). In accordance with these findings, treatment with leptin reduced the magnitude of 
LTD in Aβ1-42-treated slices. Similarly, leptin (116-130), but not leptin (22-56) attenuated the 
effects of Aβ1-42 as the magnitude of LTD was significantly decreased in the presence of 
leptin (116-130). Moreover, application of either leptin or leptin (116-130) inhibited Aβ1-42-
driven AMPA receptor removal from hippocampal synapses, whereas treatment with leptin 
(22-56) was without effect.  Thus overall these data demonstrate that leptin (116-130) mirrors 
the actions of leptin in counteracting the detrimental acute effects of Aβ1-42 on hippocampal 
synaptic function. 
Evidence is growing that leptin has neuroprotective actions in various models of 
neurodegenerative disease. In Parkinson’s disease models, treatment with leptin protects 
dopaminergic neurons from various toxic insults (Doherty et al, 2008; Weng et al, 2007), 
whereas in AD models of amyloid toxicity, leptin increases neuronal viability via activation 
of STAT3 and PI3-kinase signalling (Doherty et al, 2013; Doherty et al, 2008; Guo et al, 
2008). In this study, leptin and leptin (116-130) enhanced the survival of human neural (SH-
SY5Y) cells treated with either Aβ1-42 or Cu2+. Conversely no change in cell viability was 
evident after treatment with leptin (22-56), thereby providing further evidence that leptin 
(116-130) but not leptin (22-56) mirrors the protective actions of leptin.  
In these studies, we reveal that signalling via PI3-kinase and STAT3 is essential for leptin 
(116-130)-mediated neuroprotection as selective inhibition of these pathways eliminated the 
protective effects of leptin (116-130). Moreover, direct activation of key components of PI3-
kinase and STAT3 signalling pathways was observed following administration of leptin (116-
130). As stimulation of both PI3-kinase (Doherty et al, 2013; Doherty et al, 2008) and 
STAT3 signalling cascades (Doherty et al, 2013; Guo et al, 2008) mediate the 
neuroprotective actions of leptin, these data indicate that leptin (116-130) is activating the 
same signalling pathways as the full length leptin peptide to induce neuronal survival. This 
provides further evidence that leptin (116-130) is mirroring the neuronal effects of leptin.  
These studies demonstrate that the 116-130 fragment of the leptin molecule enhances 
hippocampal synaptic plasticity and has neuroprotective effects. As such this fragment is a 
very interesting therapeutic target to treat memory dysfunction and protect against 
neurodegeneration in the early stages of AD. To test the functional implications of the effects 
of leptin 116-130 we examined the effects of acute doses of this fragment on a test of 
episodic-like memory. This test is particularly appropriate as it models the type of memory 
that is first compromised in AD. Performance on the task has been shown to be impaired in 
rodents with damage to the lateral entorhinal cortex (Wilson et al, 2013), the first region to be 
damaged in AD, and the hippocampus (Langston and Woods, 2010). It has also been shown 
that the triple transgenic murine model of AD show impaired performance on this task at 6 
months of age (Davis et al, 2013). The current data demonstrate powerful cognitive 
enhancing effects of both leptin and leptin (116-130) as both groups performed significantly 
better than controls on the OPC task. This is the first time that leptin has been shown to 
enhance the specific type of memory that degrades in AD and the fact that this cognitive 
enhancement is also produced by leptin (116-130) suggests that this fragment is a viable tool 
to treat memory dysfunction caused by damage to the hippocampal-entorhinal network. 
Recent studies indicate that administration of leptin also protects against Aβ-induced 
impairments in spatial memory tasks (Tong et al, 2015). Thus it is feasible that administration 
of leptin (116-130) will also mirror the effects of leptin and protect against the chronic effects 
of Aβ on hippocampal-dependent learning and memory.  
The current experiments demonstrated enhancement of memory for object-place-context 
associations. Enhancement of this hippocampal dependent task is consistent with our findings 
showing enhancement of hippocampal synaptic plasticity but it remains a possibility that 
leptin 116-130 may also enhance simpler forms of recognition memory such as object 
recognition or object-place recognition. These simpler forms of recognition memory are 
dependent on other areas of the medial temporal lobe network and so future work could 
examine whether the cognitive enhancement is specific to the hippocampus or also affects the 
surrounding cortical inputs. One other consideration is the anxiolytic properties of leptin that 
have been reported in both normal (Liu et al. 2010) and chronically stressed rats (Lu et al. 
2006). Reduced anxiety could potentially affect performance on the spontaneous recognition 
tasks as less anxious animals may explore more freely. This was not found to be the case in 
the current study as the levels of exploration in both sample and test phases of the OPC 
experiment were not different between groups. This is not surprising as animals had extensive 
handling and pre-training before the OPC test and so levels of anxiety would have been very 
low in all animals. 
In conclusion, these data indicate that the leptin (116-130) fragment mirrors the cognitive 
enhancing effects of leptin as it promotes trafficking of the AMPA receptor subunit GluA1 to 
synapses, facilitates hippocampal synaptic plasticity and improves performance in an 
episodic-like memory task. In addition, leptin (116-130) counteracts the detrimental effects of 
Aβ1-42 on hippocampal synaptic function and neuronal viability in various cellular models of 
amyloid toxicity.  Our findings not only reinforce the consensus that the leptin system is an 
important therapeutic target in AD, but also establish that leptin (116-130) may be useful in 
the development of leptin-mimetic agents for therapeutic use. 
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Figure Legends  
Figure 1.  
Leptin (116-130) promotes conversion of STP into a persistent increase in synaptic 
transmission in juvenile hippocampus.  
A. Pooled data showing that primed burst stimulation (indicated by the arrow) delivered in 
the absence of leptin induced STP (filled circle) in juvenile hippocampal slices. In contrast, in 
leptin-treated slices (open circle) the same stimulation paradigm resulted in a persistent 
increase in synaptic transmission. In this and subsequent figures, each point is the average of 
four successive responses. Top, Representative synaptic records (average of four consecutive 
records) are shown for the times indicated. B, During exposure to leptin (116-130; 50nM), 
application of the primed burst stimulation paradigm resulted in a persistent increase in 
synaptic transmission (B), whereas only STP was evident in slices treated with leptin (22-56; 
C).  
 
Figure 2.  
In adult, leptin (116-130) induces a persistent increase in synaptic efficacy and increases 
GluA1 trafficking to hippocampal synapses. . 
A. Pooled data showing that application of leptin (116-130) results in a persistent increase in 
excitatory synaptic transmission in adult hippocampal slices. B, In contrast application of 
leptin (22-56) failed to alter excitatory synaptic strength. C, Representative confocal images 
of surface GluR1 staining in control cultured hippocampal neurons and after exposure to 
leptin, leptin (116-130) or leptin (22-56).  Leptin (116-130) mirrors the effects of leptin by 
increasing GluA1 surface labelling. Scale bars, 10 μm. D, Pooled data showing relative 
changes in surface GluA1 labelling in control conditions, and after exposure to leptin, leptin 
(116-130) or leptin (22-56) in hippocampal neurons. E, Pooled data of the percent co-
localisation of surface GluA1 and synaptophysin immunolabelling in cultured hippocampal 
neurons. Leptin (116-130), but not leptin (22-56) increased GluA1 surface labelling 
associated with synapses. F. Pooled data of relative changes in surface GluA1 labelling in 
hippocampal cultures in control conditions, after bpV, leptin or leptin (116-130) treatment, 
and in the presence of bpV and either leptin, or leptin (116-130). Inhibition of PTEN 
mimicked and occluded the effects of leptin (116-130). 
 
Figure 3.  
Leptin (116-130) inhibits the aberrant effects of amyloid-β (Aβ)1–42 on hippocampal 
synaptic plasticity in juvenile slices.  
A, Pooled data showing that HFS (indicated by the arrow) induces synaptic plasticity in Aβ42–
1-treated (open circles) slices, whereas Aβ1-42 inhibits synaptic plasticity (filled circles). B, 
Exposure to leptin prevented Aβ1–42-inhibition of synaptic plasticity. Treatment with leptin 
(116-130; C), but not leptin (22-56; D) reversed Aβ1–42-inhibition of synaptic plasticity.  
 
Figure 4. 
Leptin (116-130) prevents Aβ-induced AMPA receptor internalisation and facilitation of 
hippocampal LTD. 
A, Pooled data showing that the sub-threshold low frequency stimulation (indicated by the 
arrow) failed to induce long-term depression (LTD) in Aβ42–1-treated (open circles) slices, 
whereas robust LTD (filled circles) is induced in Aβ1–42-treated juvenile slices. B, Exposure to 
leptin prevented Aβ1–42-induced LTD. Similarly treatment with leptin (116-130; C), but not 
leptin (22-56; D) prevented Aβ1–42-induced LTD. E, Pooled data showing relative changes in 
GluA1 surface labelling in cultured hippocampal neurons in control (Aβ42–1) conditions  and 
after treatment with leptin, Aβ1–42, leptin (116-130), leptin (22-56) and in the presence of 
Aβ1–42 plus either leptin, leptin (116-130) or leptin (22-56), respectively. Leptin and leptin 
(116-130) prevent Aβ-driven internalisation of GluA1. 
 
Figure 5. 
Leptin (116-130) prevents copper and Aβ-induced cell death in human SH-SY5Y cells. 
A, Pooled data revealing that leptin and leptin (116-130) prevent LDH release induced by 
administration of 5M CuCl2. B, Similar pooled data was obtained for cultures treated with 
10M A1-42. C, Pooled data showing that in 5M CuCl2 treated cultures enhanced numbers 
of cells are detected with a crystal violet assay when cultures are co-treated with either leptin 
or leptin (116-130) with a similar trend observed when cultures were induced to die with 
10M A1-42, D. 
Figure 6.  
The neuroprotective effects of leptin (116-130) involve activation of STAT3 and PI3-
kinase-dependent signalling pathways 
A, Pooled data revealing that treatment of SH-SY5Y cells with the STAT-3 inhibitor 
WP1066 (5M) prevented leptin (116-130)-mediated neuroprotection from the effects of 
10M A1-42. B, Pooled data from LDH assays demonstrating that the PI3-kinase inhibitor 
wortmannin (50nM) attenuated leptin (116-130)-mediated neuroprotection against 10M 
A1-42. C, Pooled data from ELISA assays showing that leptin (116-130) stimulates 
phosphorylation of STAT3. D, Pooled data from ELISA assays showing that leptin (116-130) 
stimulates phosphorylation of Akt. 
Figure 7. 
Leptin (116-130) enhances episodic-like memory. 
A. Object-place-context task used to assess episodic-like memory. There are 2 sample phases 
in which mice are exposed to different copies of two different objects (star and hexagon) and 
allowed to explore for 3 mins. In the test phase they see two new copies of one of the objects. 
The arrow points to the object that has not been previously seen in that place within that 
context. B. Mean ± SEM discrimination index for the three groups. * indicates p<0.05. C. 
Total exploration time in the test phase is not different between groups. D. Exploration of the 
novel and familiar objects in the test phase. 
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